These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6113065)

  • 21. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
    Vakkilainen J; Steiner G; Ansquer JC; Perttunen-Nio H; Taskinen MR
    Diabetes Care; 2002 Mar; 25(3):627-8. PubMed ID: 11874962
    [No Abstract]   [Full Text] [Related]  

  • 22. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor.
    de Luis DA; Bachiller P; Aller R
    Nutrition; 2001 May; 17(5):414-5. PubMed ID: 11377136
    [No Abstract]   [Full Text] [Related]  

  • 23. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
    Kiortsis DN; Elisaf MS
    Fundam Clin Pharmacol; 2001 Dec; 15(6):401-3. PubMed ID: 11860528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of fenofibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in hypertriglyceridaemic subjects.
    Packard CJ; Caslake MJ; Shepherd J
    Monogr Atheroscler; 1985; 13():142-4. PubMed ID: 4088276
    [No Abstract]   [Full Text] [Related]  

  • 27. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
    Kowalski J; Okopień B; Madej A; Zieliński M; Belowski D; Kalina Z; Herman ZS
    Eur J Clin Pharmacol; 2003 Jul; 59(3):189-93. PubMed ID: 12756509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
    Jen SL; Chen JW; Lee WL; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.
    Corbelli JC; Bullano MF; Willey VJ; Cziraky MJ; Corbelli ME; Waugh W
    Am J Cardiol; 2002 Dec; 90(12):1388-91. PubMed ID: 12480052
    [No Abstract]   [Full Text] [Related]  

  • 33. Application of the concanavalin A precipitation technique in an evaluation of fenofibrate action on cholesterolemia in IIa and IIb hyperlipemic subjects.
    Chicaud P; Demange J; Drouin P; Debry G
    Pharmacology; 1983; 26(2):90-4. PubMed ID: 6844393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits].
    Saitoh K; Mori T; Kasai H; Nagayama T; Ohbayashi S
    Nihon Yakurigaku Zasshi; 1995 Jul; 106(1):51-60. PubMed ID: 7590523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 36. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
    Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
    Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Black soybean extract improves lipid profiles in fenofibrate-treated type 2 diabetics with postprandial hyperlipidemia.
    Kusunoki M; Sato D; Tsutsumi K; Tsutsui H; Nakamura T; Oshida Y
    J Med Food; 2015 Jun; 18(6):615-8. PubMed ID: 25651043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypolipidemic and Hepatoprotective Effects of a Polyprenol-Containing Drug in Patients with Acute Coronary Syndrome.
    Vyshlov EV; Tsoy EI; Sultanov VS; Trusov VB; Ryabov VV
    Bull Exp Biol Med; 2018 Jul; 165(3):319-321. PubMed ID: 29998439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
    Hayakawa T; Hayashi A; Miyakawa M; Shimoyama K; Sekiya S; Sekiguchi M; Inotsume N
    Yakugaku Zasshi; 2002 Feb; 122(2):169-75. PubMed ID: 11857958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.